4//SEC Filing
Patni Rajiv 4
Accession 0001209191-20-040356
CIK 0001269021other
Filed
Jul 1, 8:00 PM ET
Accepted
Jul 2, 4:37 PM ET
Size
8.8 KB
Accession
0001209191-20-040356
Insider Transaction Report
Form 4
Patni Rajiv
EVP, CMO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-07-02$7.89/sh−125,000$986,250→ 0 totalExercise: $10.11Exp: 2030-02-27→ Common Stock (125,000 underlying) - Disposition to Issuer
Restricted Stock Units
2020-07-02−35,000→ 0 total→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
- [F2]At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.
Documents
Issuer
PORTOLA PHARMACEUTICALS INC
CIK 0001269021
Entity typeother
Related Parties
1- filerCIK 0001616200
Filing Metadata
- Form type
- 4
- Filed
- Jul 1, 8:00 PM ET
- Accepted
- Jul 2, 4:37 PM ET
- Size
- 8.8 KB